SCHEMBL8904326

SCHEMBL8904326

c1ccc2cc3cc4cc5cscc5cc4cc3cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 3/20 0.46
CYP3A4 P08684 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
HIF1A Q16665 2/20 0.46
ALOX15 P16050 1/20 0.46
HBB P68871 1/20 0.46
HPGD P15428 2/20 0.39
MAPT P10636 2/20 0.39
GLA P06280 1/20 0.39
ACHE P22303 1/20 0.39
CYP2A6 P11509 6/20 0.39
ALOX12 P18054 1/20 0.39
NQO2 P16083 2/20 0.38
CYP1A2 P05177 3/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8218109 1.00 ALDH1A1 (0.46) ALDH1A1HSD17B10CYP3A4TDP1CASP1
SCHEMBL8905235 1.00 ALDH1A1 (0.46) ALDH1A1HSD17B10CYP3A4TDP1CASP1
SCHEMBL440327 0.97 ALDH1A1 (0.42) ALDH1A1HSD17B10CYP3A4TDP1CASP1
SCHEMBL240787 0.81
SCHEMBL51694 0.81
Benz(B)Anthracene SCHEMBL7947 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10CYP3A4TDP1CASP1
SCHEMBL22634171 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10CYP3A4TDP1CASP1
Benz(B)Anthracene SCHEMBL22352910 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10CYP3A4TDP1CASP1
Benz(B)Anthracene SCHEMBL3474922 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10CYP3A4TDP1CASP1
SCHEMBL25181 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10CYP3A4TDP1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11183340-B2 Method for manufacturing solid electrolytic capacitor SHOWA DENKO K.K. (JP) 2021-11-23 US disclosed
US-11136432-B2 Method for producing polyisothianaphthene-based electroconductive polymer SHOWA DENKO K.K. (JP) 2021-10-05 US disclosed
US-20200090874-A1 METHOD FOR MANUFACTURING SOLID ELECTROLYTIC CAPACITOR SHOWA DENKO K.K. (JP) 2020-03-19 US disclosed
US-20190345287-A1 METHOD FOR PRODUCING POLYISOTHIANAPHTHENE-BASED ELECTROCONDUCTIVE POLYMER SHOWA DENKO K.K. (JP) 2019-11-14 US disclosed
US-20190337919-A1 FUSED HETEROPOLYCYCLIC COMPOUND, AND METHOD FOR PRODUCING CONDUCTIVE POLYMER IN WHICH SAID COMPOUND IS USED SHOWA DENKO K.K. (JP) 2019-11-07 US disclosed
EP-3564290-A1 METHOD FOR PRODUCING POLYISOTHIANAPHTHENE ELECTROCONDUCTIVE POLYMER Showa Denko K.K. (JP) 2019-11-06 EP disclosed
EP-3564229-A1 FUSED HETEROPOLYCYCLIC COMPOUND, AND METHOD FOR PRODUCING CONDUCTIVE POLYMER IN WHICH SAID COMPOUND IS USED Showa Denko K.K. (JP) 2019-11-06 EP disclosed
EP-3564976-A1 METHOD FOR MANUFACTURING SOLID ELECTROLYTIC CAPACITOR Showa Denko K.K. (JP) 2019-11-06 EP disclosed
US-5688873-A POLYISOBENZOTHIOPHENE, POLYISOBENZOFURAN, POLYISOINDOLE AND RELATED POLYMERS, AROMATIC RESINS, SULFONATE GROUP, WATER SOLUBILITY SHOWA DENKO K.K. (JP) 1997-11-18 US disclosed
US-5648453-A Electroconductive polymer and process for producing the polymer SHOWA DENKO K.K. (JP) 1997-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337919-A1 FUSED HETEROPOLYCYCLIC COMPOUND, AND METHOD FOR PRODUCING CONDUCTIVE POLYMER IN WHICH SAID COMPOUND IS USED SCO2, SQOR, GJB2 ALDH1A1 2352/4885HSD17B10 1649/4885CYP3A4 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.